Resultados de procura - Tai‐Tsang Chen

  • Mostrando 1 - 13 Resultados de 13
Limitar resultados
  1. 1
    Statistical issues and challenges in immuno-oncology

    Statistical issues and challenges in immuno-oncology por Tai‐Tsang Chen

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors

    Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors por Tai‐Tsang Chen

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

    Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study por Neil P. Shah, Wang, Amit Roy, Andreas Hochhaus, Kantarjian, Tai‐Tsang Chen

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

    Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma por Feng Yan, Amit Roy, Eric Masson, Tai‐Tsang Chen, Rachel Humphrey, Jeffrey S. Weber

    Publicado 2013
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  5. 5
    Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)

    Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) por David F. McDermott, John B.A.G. Haanen, Tai‐Tsang Chen, Paul Lorigan, Steven O’Day

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

    Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia por Alfonso Quintás-Cardama, Jorge E. Cortés, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, David Liu, Eric Bleickardt, Tai‐Tsang Chen, Hagop M. Kantarjian

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma por Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra A. Patt, Tai‐Tsang Chen, David M. Berman, Jedd D. Wolchok

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

    Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial por Michele Maio, Jean‐Jacques Grob, Steinar Aamdal, Igor Bondarenko, Caroline Robert, L. Thomas, Claus Garbe, Vanna Chiarion‐Sileni, Alessandro Testori, Tai‐Tsang Chen, Marina Tschaika, Jedd D. Wolchok

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective

    Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective por Neil Lineberry, Jesse A. Berlin, Bernadette Mansi, Susan Glasser, Michael Berkwits, Christian Klem, Ananya Bhattacharya, Leslie Citrome, Robert E. Enck, John Fletcher, Daniel G. Haller, Tai‐Tsang Chen, Christine Lainé

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy

    Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy por Stefan Suciu, Alexander M.M. Eggermont, Paul Lorigan, John M. Kirkwood, Svetomir N. Markovic, Claus Garbe, David Cameron, Srividya Kotapati, Tai‐Tsang Chen, Keith Wheatley, Natalie Ives, Gaetan de Schaetzen, Achmad Efendi, Marc Buyse

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  11. 11
    Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias por Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Ron Paquette, Jorge E. Cortés, Susan O’Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath R. Iyer, Tai‐Tsang Chen, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

    Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358 por R. Wendel Naumann, Ana Oaknin, Tim Meyer, José M. López-Picazo, Christopher D. Lao, Yu Jeong Bang, Valentina Boni, William H. Sharfman, J.C. Park, Lot A. Devriese, Kenichi Harano, Christine H. Chung, Suzanne L. Topalian, Kam Zaki, Tai‐Tsang Chen, Junchen Gu, B. Li, Adam Barrows, Andrea Horváth, Kathleen N. Moore

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma por Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: